TTY Biopharm Company Limited AI Stock Analysis
TTY Biopharm Company Limited (4105) AI Stock Analysis
TTY Biopharm Company Limited
(TPEx:4105)
TTY Biopharm scores well on the strength of its financial fundamentals: durable high-single-digit revenue growth, superior margins for a specialty and generic drug maker, a de-levered balance sheet (debt-to-equity of 0.17) and excellent cash conversion with free cash flow at ~91% of net income. Valuation adds to the appeal, with a modest 12.2x P/E and a well-covered 5.68% dividend yield. Technicals are the weaker element — the stock holds above its 50-, 100- and 200-day averages but has lost short-term momentum, with neutral RSI and a soft stochastic reading. The key fundamental risk to monitor is the gradual erosion of gross margin, which reflects ongoing pricing competition in generics.
TTY Biopharm Company Limited (4105) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 20.31B
- Dividend Yield
- 5.48%
- Average Volume (3M)
- 612.78K
- Price to Earnings (P/E)
- 12.5
- Beta (1Y)
- 0.15
- Revenue Growth
- 4.54%
- EPS Growth
- -7.38%
- Country
- TW
- Employees
- 561
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
TTY Biopharm Company Limited Business Overview & Revenue Model
Company Description
TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncolog...
TTY Biopharm Company Limited Financial Statement Overview
Summary
TTY Biopharm shows a high-quality financial profile. Revenue has compounded to NT$6.45 billion with ~9% growth in the latest year, while margins are best-in-class for a generics maker (gross ~58%, operating 26.4%, net 24.2%) and net income rose ~8% to NT$1.56 billion. The balance sheet is conservative and improving: debt cut to NT$1.23 billion, debt-to-equity down to 0.17, and ROE of 21.5% trending higher. Cash flow is a standout, with operating cash flow up ~31% to NT$1.76 billion and free cash flow of NT$1.61 billion equal to ~91% of net income, confirming earnings quality. The main caution is the multi-year drift in gross margin from 61.7% to 57.7%, signalling pricing pressure in generics, alongside steady rather than dynamic growth.
Income Statement
83Very PositiveBalance Sheet
86Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.65B | 6.45B | 5.89B | 5.51B | 5.06B | 4.54B |
| Gross Profit | 3.82B | 3.72B | 3.41B | 3.22B | 3.02B | 2.77B |
| EBITDA | 2.23B | 1.90B | 1.73B | 1.66B | 1.50B | 1.14B |
| Net Income | 1.75B | 1.56B | 1.45B | 1.13B | 1.09B | 831.89M |
Balance Sheet | ||||||
| Total Assets | 11.83B | 11.35B | 10.86B | 9.87B | 9.60B | 9.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.94B | 2.99B | 3.08B | 2.82B | 2.68B | 2.59B |
| Total Debt | 2.11B | 1.23B | 1.76B | 1.92B | 1.87B | 2.20B |
| Total Liabilities | 4.08B | 3.30B | 3.35B | 3.37B | 3.37B | 3.53B |
| Stockholders Equity | 6.96B | 7.24B | 6.75B | 5.94B | 5.66B | 5.17B |
Cash Flow | ||||||
| Free Cash Flow | 1.81B | 1.61B | 1.22B | 985.73M | 1.10B | 1.18B |
| Operating Cash Flow | 1.96B | 1.76B | 1.35B | 1.09B | 1.24B | 1.26B |
| Investing Cash Flow | -375.17M | -367.36M | -243.56M | -2.63M | -133.14M | -168.78M |
| Financing Cash Flow | -1.35B | -1.59B | -1.05B | -816.33M | -1.10B | -850.05M |
TTY Biopharm Company Limited Peers Comparison
Overall Rating
- TW:410579Outperform
TW:662070Outperform
TW:370569Neutral
TW:178957Neutral
TW:412348Neutral
TW:474342Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4105 | 79Outperform | TWD 20.44B | 12.48 | ― | 5.48% | 4.54% | -7.38% |
| TW:6620 | 70Outperform | TWD 20.83B | 66.76 | ― | 1.52% | ― | ― |
| TW:3705 | 69Neutral | TWD 15.80B | 17.22 | ― | 5.16% | -5.14% | -1.29% |
| TW:1789 | 57Neutral | TWD 16.01B | 904.98 | ― | 1.45% | -4.75% | -90.91% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4123 | 48Neutral | TWD 22.38B | 23.82 | ― | 6.15% | 3.63% | ― |
| TW:4743 | 42Neutral | TWD 22.59B | -102.60 | ― | ― | 14.79% | 84.54% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4105 | TTY Biopharm Company Limited | 82.10 | 7.54 | 10.12% | |
| TW:1789 | Scinopharm Taiwan, Ltd. | 20.00 | 2.60 | 14.92% | |
| TW:3705 | YungShin Global Holding Corp. | 58.10 | 5.90 | 11.30% | |
| TW:4123 | Center Laboratories, Inc. | 28.40 | -5.05 | -15.09% | |
| TW:4743 | Oneness Biotech Co., Ltd. | 46.25 | -16.55 | -26.35% | |
| TW:6620 | Handa Pharmaceuticals Inc | 136.50 | 16.48 | 13.73% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026